Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vibegron for Prevention of Ureteral Stent-Related Symptoms
jRCTs061240140Recruiting
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of vibegron in ureteral stent-related symptoms (USRS) and overactive bladder (OAB) (2 arms). Primary endpoints: Change in OABSS at 2 weeks and Change in VAS pain score at 2 weeks. Started May 2025; status: recruiting.
02
Drugs
vibegron
03
Conditions
ureteral stent-related symptoms (USRS)overactive bladder (OAB)
Beyond the preview
Go deeper on jRCTs061240140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061240140.